Other Events ·
GSK announced positive overall survival data from the ARTEMIS-008 phase III trial in China, where its B7-H3-targeted…
GLAXFGSK plc
GSK announced positive overall survival data from the ARTEMIS-008 phase III trial in China, where its B7-H3-targeted antibody-drug conjugate Ris-Rez reduced the risk of death by 54% versus topotecan (HR 0.46; p<0.0001). Patients receiving Ris-Rez achieved a median overall survival of 18.5 months compared to 10.3 months for the comparator, with fewer severe treatment-related side effects (60.9% vs 78.2%). GSK holds exclusive rights to develop and commercialize Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan, advancing a global clinical program including the phase III EMBOLD SCLC-301 trial with pivotal data expected next year. This filing highlights significant clinical progress for GSK's oncology pipeline in the biopharmaceutical industry.